| Filed On | Filing |
|---|---|
| 21 Jul 2022 |
8-K/A: Financial Statements and Exhibits
On March 25, 2022, Axsome Therapeutics, Inc. (the “Company" or "acquirer”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Jazz Pharmaceuticals plc, pursuant to which the Company will acquire Sunosi (the “Product... |
| 31 Mar 2022 |
8-K/A: Entry into a Material Definitive Agreement
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. |
| 22 Sep 2020 |
8-K/A: Other Events
Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting |
Loading...